This study is conducted in Japan. The aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (NovoSeven®) and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.

Inclusion Criteria:

• Treated with eptacog alpha (NovoSeven®)

Exclusion Criteria:

• Investigator decision to measure for antibody as unnecessary medical testing

Patients from general practice setting who have been deemed appropriate to receive NovoSeven® (eptacog alpha) as new treatment and as part of routine out-patient care by the prescribing physician